We use cookies to provide you with a better experience. By clicking the Accept button, you are agreeing to our use of cookies in accordance with our Privacy Policy.
  • Patient Resources
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
    • Glossary
  • Professional Resources
    • Research Center Profiles
    • Industry Provider Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
  • About Us
  • Contact Us
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Canasa (mesalamine)

  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Canasa (mesalamine)

  • Profile

Profile

Contact Information

Currently Enrolling Trials

    Show More

    General Information

    Canasa (mesalamine) is a rectal suppository that has been approved by the FDA for the treatment of active ulcerative proctitis. Ulcerative proctitis is a less severe form of ulcerative colitis - a disease that causes inflammation and ulcers in the top layers of the lining of the large intestine. Ulcerative proctitis differs from ulcerative colitis in terms of where the inflammation occurs. In ulcerative proctitis, inflammation is only present in the rectum, and the upper limit of inflammation is visible via sigmoidoscopy. In ulcerative colitis, inflammation usually occurs in the rectum and lower part of the colon, but it may affect the entire colon.

    In August 1999, the FDA requested that Axcan sell Canasa in the United States under a temporary, emergency measure due to the lack of any other source of supply. Subsequently, Axcan performed preclinical and clinical studies and filed an NDA on April 28, 2000. In conjunction with the approval, Axcan will perform a clinical study in children ages 12-18 years with active or quiescent (inactive) disease, since this condition may also be diagnosed at a young age.

    Side Effects

    Side effects that may occur with the use of drugs containing mesalamine include (but are not limited to) the following:


    • Allergic reaction
    • Nausea or vomiting
    • Abdominal cramping
    • Headache
    • Dizziness
    • Chills

    Mechanism of Action

    The manner in which mesalamine provides a therapeutic effect for ulcerative proctitis is currently unknown.

    Additional Information

    For additional information on Canasa, please visit Axcan's web site.

    Approval Date: 2001-01-01
    Date Created: 2001-03-26 12:00:00
    Company Name: Axcan
    Back to Listings

    Upcoming Events

    • 16Dec

      Master the Regulatory Pathway for Cell & Gene Therapy Submissions: Strategies for Successful BLAs

    Featured Products

    • Regenerative-medicine-steps-to-accelerate-development-pdf

      Regenerative Medicine: Steps to Accelerate Development — PDF

    • Clinical-trial-agreements-a-guide-to-key-words-and-phrases-pdf

      Clinical Trial Agreements: A Guide to Key Words and Phrases — PDF

    Featured Stories

    • Ich_logo

      ICH Overhauls 22-Year-Old Clinical Studies Guideline

    • Survey_chart2019

      Sponsors, CROs Doing Better, Sites Say, But More Work Is Needed

    • China-360x240

      U.S. Tops List of Trial Startups With China Making Progress in Phase 1

    • Phoneapp-360x240

      Device Apps Present Unique Risks in Trials

    New!

    2019 Site Survey Reports

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2019. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing